Surrey Heartlands

Joint Formulary & PAD

Rivaroxaban - Prevention of atherothrombotic events - coronary or peripheral artery disease

You are here : Home > Formulary Search > Rivaroxaban - Prevention of atherothrombotic events - coronary or peripheral artery disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
SPC
Restrictions / Comments :

Documentation

Guidelines (Local)
Rivaroxaban prevention of atherothrmbotic events - Guidance - July 2022.pdf
NICE Technology Appraisal
NICE TA607 - Rivaroxaban for preventing artherothrombotic events in people with coronary or peripheral artery disease

PAD Profile

ChemicalSubstance :
Rivaroxaban
Indication :
Prevention of atherothrombotic events - coronary or peripheral artery disease
Group Name :
Keywords :
anticoagulant cards, anticoagulant alert cards, NOAC, DOAC, direct oral anticoagulant, PAD, coronary artery disease, CAD, arterial disease
Brand Names Include :
Xarelto
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Rivaroxaban is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Prevention of atherothrombotic events - coronary or peripheral artery disease.

  • No records returned.

Committee Recommendations (1)

06 Jul 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree that rivaroxaban is a treatment option for people with coronary or peripheral artery disease in line with NICE TA 607.

Rivaroxaban will be given a GREEN traffic light status for this indication

The APC recognises that the difference between the benefits and risks is small, but the APC supports prescribing for PAD or CAD, in those patients where the clinicians have identified (with shared decision making, and as part of a routine review) that the patient is likely to benefit from treatment with rivaroxaban.